AstraZeneca PLC AZN
News
AstraZeneca's Klygefa Gets U.S., E.U. Approval
AstraZeneca Gets FDA Approval for Bladder Cancer Treatment
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
AstraZeneca Hypertension Drug Wins Nod From EU Regulator
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
AstraZeneca to Acquire Omniose
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
AstraZeneca results: 9M and Q3 2026
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
AstraZeneca, Daiichi Sankyo Drug Gets EU Nod in Early-Stage Breast Cancer
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca Adds New Indication for Ultomiris Drug in Rare Kidney Disease


